Hims enters testosterone market

Telehealth giant Hims launched testosterone replacement therapy for cisgender men, offering injectable treatments and an oral pill after at-home blood tests.

Hims wants to test millions

Peter Stahl, a urologist and senior vice president of men's health at Hims, wants to cast as wide a net and get as many people tested as possible.

“cast as wide a net, and get as many people tested, as possible”

Hims grew from startup to public company

Hims started selling erectile dysfunction medications in two thousand seventeen and has expanded into women's health, now serving two point nine million customers.

Stahl sees underdiagnosed condition

Stahl says testosterone deficiency is really underdiagnosed and really misunderstood, with stigma created by the nineteen ninety Anabolic Steroids Control Act.

“really underdiagnosed and really misunderstood”

Testosterone became political issue

Pentagon chief Pete Hegseth announced mandatory testosterone deficiency screening for most male troops. Texas Republicans used low T as an insult in a Senate race.

Testosterone requires doctor oversight

Unlike other telehealth treatments, testosterone is a controlled substance requiring synchronous care. Patients must have a video chat with a clinician before getting a prescription.

Hims uses at-home blood collection

Hims sends patients a Tasso blood collection device that sticks to the upper arm and uses microneedles to collect a sample. Labs test twenty one biomarkers including testosterone.

Hims takes conservative approach

Stahl says if you are asymptomatic, it does not matter what your testosterone level is, you will not get treated on Hims' platform, unlike clinics offering it as anti-aging.

“If you're asymptomatic, it doesn't matter what your testosterone level is, you're not going to get treated on our platform”